Liminatus Pharma LLC (“Liminatus”), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp (“Iris”) (Nasdaq: IRAA), a publicly traded special purpose acquisition company (“SPAC”) formed for the purpose of acquiring or merging with one or more businesses, announced Wednesday they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed “Liminatus Pharma, Inc.”.
Read the full article: Liminatus Pharma LLC and Iris Acquisition Corp to Combine to Incorporate and Accelerate Much-Needed Cancer Treatments //
Source: https://www.businesswire.com/news/home/20221130006177/en/Liminatus-Pharma-LLC-and-Iris-Acquisition-Corp-to-combine-to-incorporate-and-accelerate-much-needed-cancer-treatments